Expired activity
Please go to the PowerPak homepage and select a course.

Oncology Consults: The Latest on the Biosimilar Revolution

This continuing education activity is provided by

This activity is supported by an educational grant from Amgen.


June 28, 2019


June 27, 2020


Sanjiv S. Agarwala, MD
Chief of Medical Oncology and Hematology
St. Luke's Cancer Center
Bethlehem, PA
Professor of Medicine
Temple University
Philadelphia, PA
Disclosures: No relevant financial relationships to disclose.

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
Clinical Coordinator of Hematology/Oncology
The University of Arizona Cancer Center
Clinical Assistant Professor
The University of Arizona College of Pharmacy
Phoenix, AZ
Disclosures: Consulting Fee: Amgen, Sandoz


Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


In accordance with the Accreditation Council for Pharmacy Education's Standards for Commercial Support, all CPE providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of CPE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CPE activity content over which the individual has control.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Credit Designation

This program is acceptable for 0.75 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-19-003-H01-P, effective 6/28/2019. This is a knowledge-based activity and there is no fee to attend.

This enduring material is approved for 1 year from the date of original release, June 28, 2019 to June 27, 2020.

How to Participate in This Activity and Obtain CPE Credit

To participate in this activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue a statement of participation. Your CPE credit will be reported directly to CPE Monitor within 30 days of successful completion of the activity.


Several of the most-used cancer drugs are biologics, and many, including rituximab, bevacizumab, and trastuzumab, have biosimilars available and others that are currently in late-stage clinical development. In the United States, biosimilars have been approved for use since September 2015, yet oncologists, oncology nurses, and pharmacists lack knowledge regarding the differences between biosimilars and their reference products, as well as the clinical implications of biosimilars. Moreover, considering these knowledge gaps, providers are ill-equipped to discuss biosimilars with their patients, which negatively impacts shared decision-making and patient-centered care. This continuing education activity, led by expert clinicians, will educate oncology health care professionals about the latest advances regarding the use biosimilars and how they can be applied in oncology practice.

Target Audience

The intended audience for this activity is oncologists, oncology pharmacists, and other health care professionals involved in the management of patients with cancer who may benefit from biologic therapy.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Explain the differences between biologics and their reference biologic compound in terms of structure, manufacturing, regulation, and/or clinical properties.
  • Evaluate the current FDA standards to evaluate and approve biosimilars and implications for providers, payors, and patients.
  • Assess the latest evidence regarding available and late-stage biosimilars.
  • Assess effective strategies to address common patient concerns regarding the use of biosimilars.

Educational Tools

For downloadable educational resources, visit below.

For a full list of all the educational tools available through Vindico Medical Education, please visit: www.VindicoCME.com/educationaltools.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CPE Questions?

Contact us at CME@VindicoCME.com